SGLT2 Inhibitor Adherence and Diabetes Hospitalization Risk in Type 2 Diabetes.
OBJECTIVES Emerging evidence shows that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve glycemic control and reduce the risk of cardiovascular-related mortality. This is contingent on adherence, yet evidence of SGLT2 inhibitor adherence and associated diabetes-related clinical outcomes in real-world settings...